Virtual Presentation

Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Source: Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Faculty:

Nicholas J. Vogelzang, MD

CREDIT INFORMATION

Release Date: March 16, 2009

Expiration Date: March 15, 2010

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Distinguish criteria to determine when a patient with prostate cancer is castrate resistant
Describe the results of clinical trials of bone-targeted agents to treat bone metastases in patients with prostate cancer
Compare results of clinical trials of chemotherapies and novel agents for the treatment of prostate cancer
Discuss alternative treatment regimens for prostate cancer patients who fail docetaxel
Cite patient-specific factors that influence the choice of treatment in the setting of castrate-resistant prostate cancer

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.